Mark Cuban's plan to shake up healthcare with "Cost-Plus Drugs"

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

How much time does Mark Cuban spend thinking about health care? Why does he think TrumpRx, a direct drug purchasing platform that the Trump administration aims to launch, is “the most incredible program ever”? And what are his thoughts on sports betting?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Cuban comes on for an extensive chat about the latest biosimilar launch by his company, Cost Plus Drugs, as well his broader thoughts on the drug industry and how the direct-to-consumer field is changing.

We also chat about the news this week, including more M&A deals and an upcoming Alzheimer’s readout from Novo Nordisk.

To learn more on the Cost Plus Drugs’ new biosimilar offering, go here; to read more on Abbott’s acquisition of Exact Sciences, go here; for more on Johnson & Johnson’s acquisition of Halda Therapeutics, go here; to read more on the mixed data from Agios Pharmaceuticals’ sickle-cell disease drug, go here; and for more on Novo’s upcoming Alzheimer’s readout, go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.